Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.54 |
| ▸ | TK2 | O00142 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TYMS | P04818 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888050 | 1.00 | TK1 (0.54) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL889575 | 1.00 | TK1 (0.54) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL12570191 | 1.00 | TK1 (0.54) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL888380 | 0.92 | TK1 (0.53) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL16728033 | 0.92 | TK1 (0.53) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL889670 | 0.92 | TK1 (0.53) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL888378 | 0.92 | TK1 (0.53) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL2065151 | 0.92 | TK1 (0.53) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL10178026 | 0.92 | TK1 (0.53) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL14680014 | 0.92 | TK1 (0.53) | TK1TK2LMNASMN1; SMN2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125856-B1 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20160101188-A1 | NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS | UNIV CINCINNATI (US) | 2016-04-14 | — | — | US | disclosed |
| US-8969535-B2 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| WO-2014194250-A2 | NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS | UNIVERSITY OF CINCINNATI (US) | 2014-12-04 | — | — | WO | disclosed |
| US-20130072388-A1 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2013-03-21 | — | — | US | disclosed |
| US-8361727-B2 | 3′OH-unblocked, nucleotides and nucleosides base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110287427-A1 | 3'OH-UNBLOCKED, NUCLEOTIDES AND NUCLEOSIDES BASE MODIFIED WITH LABELS AND PHOTOCLEAVABLE, TERMINATING GROUPS AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-7964352-B2 | 3′-OH unblocked nucleotides and nucleosides, base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7897737-B2 | Polymorphic identification; fluorescent dyes | LASERGEN, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090081686-A1 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20080132692-A1 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | AGILENT TECHNOLOGIES, INC. | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132692-A1 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | UNG, DCLRE1B, NT5C3B | TK1 58/4885TK2 167/4885LMNA 131/4885 |
| US-20160101188-A1 | NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS | DCTD, TYMS, CDA | TK1 28/4885TK2 123/4885LMNA 1042/4885 |
| US-20130072388-A1 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN IN DNA SEQUENCING | UNG, NT5C3B, OGG1 | TK1 62/4885TK2 160/4885LMNA 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.